Начало・Списък с акции・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Затворен

СекторЗдравеопазване

13.25 3.27

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.53

Максимум

13.62

Ключови измерители
By Trading Economics
Приходи	-1.2M -13M
Продажби	-1.5M 17M
EPS	-0.45
Марж на печалбата	-76.292
Служители	120
EBITDA	-958K -8.6M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+54.44% upside

Дивиденти
By Acuity
Следващи печалби	7.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-52M 370M
Предишно отваряне	9.98
Предишно затваряне	13.25

Настроения в новините

By Acuity

31%

69%

97 / 340 Класиране в Healthcare

ENANTA PHARMACEUTICALS INC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:23 ч. UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31.07.2026 г., 20:06 ч. UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30.07.2026 г., 19:45 ч. UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29.07.2026 г., 18:26 ч. UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28.07.2026 г., 20:06 ч. UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27.07.2026 г., 18:36 ч. UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24.07.2026 г., 20:06 ч. UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21.07.2026 г., 19:31 ч. UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20.07.2026 г., 19:46 ч. UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Сравнение с други в отрасъла

Ценова промяна

ENANTA PHARMACEUTICALS INC Прогноза

Ценова цел

By TipRanks

54.44% нагоре

12-месечна прогноза

Среден 20 USD 54.44%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за ENANTA PHARMACEUTICALS INC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на ENANTA PHARMACEUTICALS INC през последните 3 месеца.

Настроение

By Acuity

97 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.